Representative biology, made discovery-ready.

GeneVault sources the research cohorts others can't, then turns multimodal genomic, clinical, imaging, and biospecimen-linked data into discovery-ready assets through custom cohort curation today and the Global BioIntelligence Platform in development.

The widening representation gap

96 of every 100 genomes behind modern medicine are of European ancestry.

The entire rest of the world is just 4, down from 11 only five years ago, and still falling.

European ancestry Everyone else 4 in 100
Dense in today's data Where GeneVault sources, 50+ countries Active sourcing & foundation model regions
GWAS Diversity Monitor, Leverhulme Centre for Demographic Science, Oxford (2026). 95.7% European ancestry, up from 89.3% in 2020.
The data layer · the foundation of everything we do

The Global BioIntelligence Network.

Everything GeneVault delivers draws on one growing data network that combines large, diverse population cohorts with specialist disease-specific datasets, the shared data source behind both our custom cohort curation and our AI models. It is the asset a competitor cannot simply buy, and it is what lets us source the right data for almost any study, wherever that data lives.

Population breadth

The populations science has missed

Large, diverse, multimodal cohorts across Africa, Asia, the Middle East, and Latin America, regions that hold some of the world's most genetically diverse yet least-studied populations.

Specialist depth

The conditions science has underserved

Rare-disease and therapeutic-area-specific datasets curated wherever they exist, including uniquely sourced cohorts from the US and Europe, so a study can reach the exact population, condition, or modality it needs.

54M+
patient lives
50+
countries and expanding
Multi-Modal
omic, clinical, imaging & biospecimen-linked
Pan-Therapeutic
precision oncology to rare disease
What the network holds

Genomics

Whole-genome and whole-exome sequencing across diverse ancestries.

Multi-omics

Proteomics, transcriptomics, and further omics layers in phased rollout.

Longitudinal Clinical Data

Linked electronic health records, treatment timelines, and outcomes over time.

Imaging & Digital Pathology

Whole-slide images, radiology, and ophthalmic imaging with matched metadata.

Biospecimen-linked Datasets

Sample-backed cohorts that enable prospective assays where a study needs them.

Deep Phenotypic Data

Rich clinical phenotyping to power stratification and target validation.

GeneVault is part of the Count Us In movement, working to bring under-represented data out of silos and into global science. Learn more →

Global BioIntelligence Today

Fit-for-purpose cohorts, sourced wherever the right data lives.

GeneVault designs and delivers custom research cohorts for biopharma, biotech, AI, and academic teams. Drawing on our Global BioIntelligence network, we build each cohort to your protocol's specific inclusion, modality, and endpoint requirements, across populations, diseases, and therapeutic areas, from large, diverse cohorts in underrepresented regions to specialist datasets uniquely sourced in the US and Europe. Where a programme requires data that does not yet exist, we can commission new sample collection and prospective assays through the network.

Global cohort sourcing Genomics & multi-omics Longitudinal clinical & outcomes Imaging & digital pathology Biospecimen-linked datasets Prospective assay commissioning Feasibility & cohort scoping Data harmonisation

Representative examples of the work we do

Example · Oncology · Digital pathology

Recurrence-risk assay for HR+/HER2- breast cancer

Brief: a prognostic AI model to predict late distant recurrence in hormone-receptor-positive, HER2-negative early-stage disease, to support treatment de-escalation decisions.
Assembled: 1,000 patients with digitised whole-slide H&E resection images at 40x, QC-filtered for artefacts, linked to staging, receptor status, treatment, and recurrence outcomes across a 15-year diagnosis window.
Niche capability: pathology imaging plus structured outcomes, at model-training scale
Example · Oncology · Longitudinal multimodal

Unresectable Stage III NSCLC on the PACIFIC regimen

Brief: characterise response and progression in patients receiving concurrent chemoradiotherapy followed by durvalumab consolidation.
Assembled: a longitudinal cohort with serial CT/PET, radiotherapy planning data (RTSTRUCT, RTDOSE), PD-L1 expression, and clinical timelines to two years post-treatment, APAC-led with US coverage.
Niche capability: imaging, radiation dosimetry, and biomarker-linked longitudinal follow-up
Example · Immunology · Multi-omics feasibility

Molecular stratification in rheumatoid arthritis

Brief: identify responder subpopulations for an early-stage RA asset by linking molecular signatures to clinical phenotype.
Assembled: a feasibility cohort pairing serum proteomics with tissue whole-exome or RNA sequencing, on a backbone of longitudinal EMR and disease-activity measures, uniquely sourced across the US and Europe.
Niche capability: linked multi-omics plus deep clinical phenotyping in specialist markets
01Consent-backed, ethically governed sourcing
02GDPR & HIPAA compliant privacy and security
03Harmonised to a common data model
04Delivered via a Trusted Research Environment
The Future of Global BioIntelligence
The AI layer · Global BioIntelligence Platform

A biology foundation model trained on the world's underrepresented populations.

The Global BioIntelligence Platform is the AI built on the Network: it extends GeneVault's ability to transform representative biology into discovery-ready intelligence. Powered by a foundation model trained across diverse populations, diseases, and multimodal datasets, it is being designed to uncover biological insights, validate discoveries, and help researchers build a more complete understanding of human health.

Representative intelligence, without taking custody of the data

The model is trained across the network using federated learning. Institutions keep stewardship of their data, and only model gradients move between sites. This is how GeneVault builds representative intelligence without asking communities to give up control of their data.

01
Target discoverySurfacing therapeutic targets from diverse-population biology.
02
Variant interpretationReclassifying variants of uncertain significance using ancestrally diverse data.
03
Protective & resilience genomicsIdentifying variants that protect, as inputs to new therapies.
04
Biomarker discovery & stratificationFinding and segmenting responders across populations.
05
Gene therapy researchDiverse-population targets as validated outputs.
06
Population-scale insightBiological understanding at a scale no single dataset allows.
From risk-increasing and protective genetic variants to validated therapeutic targets.
GeneVault is the discovery and validation layer for diverse populations, not a therapeutics company. We surface and validate targets; our partners develop the therapies.
Why representation matters

Representation is more than ancestry. It's every dimension that makes discovery generalizable.

When biomedical data reflects only a narrow slice of humanity, and only the conditions that slice happens to have, therapies and diagnostics fail to generalise. GeneVault sources for representation across every axis that matters.

Ancestry & ethnicity

Diverse genetic backgrounds where most reference data reflects a single dominant population.

Sex & gender

Balanced cohorts in areas like cardiometabolic and autoimmune disease, where trials have historically skewed.

Rare disease

Hard-to-reach conditions, from lysosomal storage disorders to inherited kidney disease, too often left out of large datasets.

Therapeutic area

Deep, condition-specific cohorts spanning oncology subtypes, immunology, and beyond.

Flawed precision medicine

Models built on narrow data do not generalise. Representative data fixes that at the source.

Missed biological discovery

Diverse genomes and under-studied conditions carry unique signals, protective variants, and novel targets that remain invisible.

Collaboration-centric approach

Diversity, governance, and community participation compound into a true discovery platform, not just data assets.

Trusted by the organisations setting the standard for global biomedical data.

5 of Top 10global pharma engaged on cohort programmes
15+biopharma, AI, and data platform partners
50+countries contributing health data

Aligned with leading data standards, and compliant by design

Global Alliance for Genomics and Health Trust Valley GDPR compliant HIPAA compliant
Representative biology, made discovery-ready.
Start the Conversation Connect on LinkedIn
Building Global BioIntelligence

GeneVault® transforms representative biology into discovery-ready assets through custom cohort curation, AI-powered discovery, and global data partnerships. Powered by a growing network spanning 54M+ patient lives across 50+ countries, Global BioIntelligence helps bring more of the world's biology into biomedical discovery.

Contact
contact@genevault.com LinkedIn

Cambridge Innovation Center
1 Broadway, Kendall Square
Cambridge, MA 02142

© GeneVault®. All rights reserved. Privacy Policy  ·  Terms of Service